文献速递神经肿瘤

胶质瘤术前相对脑血容量分析可预测生存并降低活检采样误差风险

Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling error.
PubMed 文献 · J Neurooncol · 2017-11-02

该回顾性研究纳入146例新诊断胶质瘤(WHO II-IV级)患者,比较术前MRI相对脑血容量(rCBV)分析与组织病理学分级对总生存的预测价值。rCBV分层与WHO分级类似地将患者分为低、中、高风险组,且rCBV每增加1.0单位风险比为1.12(p<0.002)。13例活检后切除患者中3例(23%)升级,其术前rCBV均高于均值至少一个标准差,提示可能低估分级。

要点

  • rCBV分层与WHO分级类似地预测胶质瘤患者总生存。
  • rCBV每增加1.0单位,风险比为1.12(p<0.002)。
  • rCBV与病理不一致可能有助于识别低估分级风险较高的患者。

核心结论

  • rCBV可类似于病理确定的WHO分级预测胶质瘤患者的总生存。
  • rCBV分析与组织病理学不一致可能有助于识别低估分级风险较高的患者。

研究设计与样本

  • 回顾性识别146例新诊断胶质瘤(WHO II-IV级)患者,术前接受MRI rCBV分析。
  • 比较按病理WHO分级和按rCBV分层的总生存,采用Kaplan-Meier生存曲线和Cox比例风险模型。
  • 比较13例活检后行切除患者的术前影像发现与初始病理诊断。

主要发现

  • 按WHO分级和rCBV分层的生存曲线类似地将患者分为低、中、高风险组,更高分级或rCBV分层对应更短生存。
  • WHO III级 versus II级的风险比为3.91(p=0.018),IV级 versus II级的风险比为11.26(p<0.0001)。
  • rCBV每增加1.0单位的风险比为1.12(p<0.002)。
  • 13例活检患者中3例(23%)在后续切除后升级。
  • 3例升级患者术前rCBV至少高于均值一个标准差,提示低估分级;10例诊断一致患者无此表现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Appropriate management of adult gliomas requires an accurate histopathological diagnosis. However, the heterogeneity of gliomas can lead to misdiagnosis and undergrading, especially with biopsy. We evaluated the role of preoperative relative cerebral blood volume (rCBV) analysis in conjunction with histopathological analysis as a predictor of overall survival and risk of undergrading. We retrospectively identified 146 patients with newly diagnosed gliomas (WHO grade II-IV) that had undergone preoperative MRI with rCBV analysis. We compared overall survival by histopathologically determined WHO tumor grade and by rCBV using Kaplan-Meier survival curves and the Cox proportional hazards model. We also compared preoperative imaging findings and initial histopathological diagnosis in 13 patients who underwent biopsy followed by subsequent resection. Survival curves by WHO grade and rCBV tier similarly separated patients into low, intermediate, and high-risk groups with shorter survival corresponding to higher grade or rCBV tier. The hazard ratio for WHO grade III versus II was 3.91 (p = 0.018) and for grade IV versus II was 11.26 (p < 0.0001) and the hazard ratio for each increase in 1.0 rCBV units was 1.12 (p < 0.002). Additionally, 3 of 13 (23%) patients initially diagnosed by biopsy were upgraded on subsequent resection. Preoperative rCBV was elevated at least one standard deviation above the mean in the 3 upgraded patients, suggestive of undergrading, but not in the ten concordant diagnoses. In conclusion, rCBV can predict overall survival similarly to pathologically determined WHO grade in patients with gliomas. Discordant rCBV analysis and histopathology may help identify patients at higher risk for undergrading.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. McCullough BJ, Ader V, Aguedan B, et al. Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling error. J Neurooncol. 2017. PMID: 29098571. doi:10.1007/s11060-017-2642-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。